Ertapenem Sodium, CAS# 153773-82-1 is a carbapenem-type antibiotic. Also known as the brand name Invanz, which is marketed by Merck, the patent for Invanz is expiring on November 21, 2015, opening the market for generic pharmaceutical options of this powerful antibiotic. Ertapenem sodium is unique in that it is extremely efficacious for treating a variety of tough bacterial infections. It is indicated for the treatment of complicated intra-abdominal infections due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, and Bacteroides uniformis. Additionally, ertapenem is effectual for treating complicated skin and skin structure infections, diabetic foot infections without Osteomyelitis, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Streptococcus agalactiae, Peptostreptococcus species, Porphyromonas asaccharolytica, community acquired pneumonia, complicated urinary tract infections including Pyelonephritis, acute pelvic infections Including Postpartum Endomyometritis, post surgical gynecologic infections and the prophylaxis of surgical site infection following elective colorectal surgery.
Administration of ertapenem sodium is done via an intramuscular injection for up to 7 days, or an intravenous drip for up to 14 days. With an I.V. infusion ertapenem should be infused over a period of 30 minutes. Adults and adolescents older then 13 years of age typically receive 1 gram given once a day. Children ages 3 months to 12 years of age should receive 15 milligrams/kilograms twice a day. Their dose should not exceed 1 gram a day. There is a possibility of seizures if ertapenem is administered alongside valproic acid or divalproex sodium. The concomitant use of ertapenem and valproic acid/divalproex sodium is not recommended. Common side effects of ertapenem include infused vein complication, diarrhea, nausea and headache.
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria, and has been proven efficacious throughout many trials. One such trial involved the treatment of complicated skin and skin structure infections in adults. This randomized, double-blind trial compared 1 gram of ertapenem given intravenously once daily with an intravenous dose of 3.375 grams of piperacillin/tazobactam. The piperacillin/tazobactam combination was administered every 6 hours. The patients were given one of the two medication/medication combinations for at least 7 and up to 14 days. Of the 540 patients enrolled, all were afflicted with deep soft tissue abscess, posttraumatic wound infection and cellulitis with purulent drainage. Positive findings emerged, and the clinical success rate at 10-21 days post-therapy with ertapenem was a hefty 83.9 percent. The drug combination of piperacillin and tazobactam also had similar success rates.
Another study which evaluated adults being treated for acute pelvic infections proved successful for patients who received ertapenem. With 412 patients enrolled, this randomized and double-blind trial compared ertapenem (1 gram intravenously once a day) with piperacillin/tazobactam (3.375 grams intravenously every 6 hours) for 3 to 10 days. The post-therapy rates declaring success at 2-4 weeks after treatment indicated a solid 93.9 percent positive test of cure rate for participants who were dosed with ertapenem. The group of patients dosed with the piperacillin and tazobactam combination showed a 91.5 percent improvement. Ertapenem sodium has been deemed safe for both pediatric and adult patients, and continues to prove it’s reliability and tolerability year after year. LGM Pharma is a provider of the API ertapenem sodium, and offers clients support throughout the entire research and development process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.